#FollowMe - Spotlight on Atrineo AG: driving innovation transfer and communication in NOMAD

This week, we shine a light on Atrineo AG, one of the core partners in the NOMAD project. Their contributions are integral to ensuring the success of our mission to revolutionize dental healthcare through innovative solutions.

💡 Follow Me This Week:

Dr. Sylwia Sekula-Neuner is spearheading the preparation of a detailed progress report for the upcoming consortium meeting in Sallanches, France. Her efforts will provide the consortium with strategic insights and highlight key milestones, guiding discussions on the next phases of the project.

Meanwhile, Emilie Kärcher has been conducting in-depth patent research to evaluate the intellectual property landscape. Her work is essential for protecting NOMAD’s innovations and positioning our solutions effectively in the competitive medical device market.

Why Intellectual Property research matters?

Atrineo ensures that NOMAD’s groundbreaking ideas are both innovative and safeguarded. By mapping existing patents and uncovering opportunities for innovation, their work provides a solid foundation for clinical trials and commercialization. This ensures that our advanced dental implant solutions remain protected from competitors and viable in the long term.

Coordinating communication across borders

Atrineo plays a vital role in managing communication within the project. With 10 partner organizations across seven European countries, seamless coordination is key. As part of the Communication and Dissemination Work Package, Atrineo focuses on:

• Content Creation: Simplifying complex research into engaging stories for websites, social media, and public platforms.
• Public Engagement: Amplifying NOMAD’s breakthroughs through conferences, digital campaigns, and strategic outreach to connect with diverse audiences.

Beyond communication: Innovation Management

Atrineo’s expertise goes beyond communication and intellectual property. They are leaders in:

• Market Analysis: Understanding industry trends to align NOMAD’s innovations with market needs.
• Technology Transfer: Ensuring NOMAD’s technologies transition seamlessly from lab to market.
• Regulatory Strategy: Navigating compliance frameworks to facilitate clinical application.
• Cost-Benefit Analysis: Evaluating the economic impact of NOMAD’s innovations.

Looking Ahead

As we approach the consortium meeting in November 2024, Atrineo’s work remains central to the project’s success. Their contributions will be instrumental in guiding discussions, aligning project goals, and driving NOMAD’s transformative impact on dental healthcare.

Stay tuned for more updates as we continue to follow Atrineo AG’s pivotal work within the NOMAD consortium!

November 2024

Follow us on LinkedIn